Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
Simon J Crabb, Gareth Griffiths, Ellice Marwood, Denise Dunkley, Nichola Downs, Karen Martin, Michelle Light, Josh Northey, Sam Wilding, Amy Whitehead, Emily Shaw, Alison J Birtle, Amit Bahl, Tony Elliott, Charlotte Westbury, Santhanam Sundar, Angus Robinson, Satinder Jagdev, Satish Kumar, Claire Rooney, Carolina Salinas-Souza, Christine Stephens, Vincent Khoo, Robert J Jones, Simon J Crabb, Gareth Griffiths, Ellice Marwood, Denise Dunkley, Nichola Downs, Karen Martin, Michelle Light, Josh Northey, Sam Wilding, Amy Whitehead, Emily Shaw, Alison J Birtle, Amit Bahl, Tony Elliott, Charlotte Westbury, Santhanam Sundar, Angus Robinson, Satinder Jagdev, Satish Kumar, Claire Rooney, Carolina Salinas-Souza, Christine Stephens, Vincent Khoo, Robert J Jones
Abstract
Purpose: Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and synergism with docetaxel.
Patients and methods: ProCAID was a placebo controlled randomized phase II trial in mCRPC. Patients received up to ten 21-day cycles of docetaxel (75 mg/m2 intravenous, day 1) and prednisolone (5 mg twice daily, oral, day 1-21) and were randomly assigned (1:1) to oral capivasertib (320 mg twice daily, 4 days on/3 days off, from day 2 each cycle), or placebo, until disease progression. Treatment allocation used minimization factors: bone metastases; visceral metastases; investigational site; and prior abiraterone or enzalutamide. The primary objective, by intention to treat, determined if the addition of capivasertib prolonged a composite progression-free survival (cPFS) end point that included prostate-specific antigen progression events. cPFS and overall survival (OS) were also assessed by composite biomarker subgroup for PI3K/AKT/PTEN pathway activation status.
Results: One hundred and fifty patients were enrolled. Median cPFS was 7.03 (95% CI, 6.28 to 8.25) and 6.70 months (95% CI, 5.52 to 7.36) with capivasertib and placebo respectively (hazard ratio [HR], 0.92; 80% CI, 0.73 to 1.16; one-sided P = .32). Median OS was 31.15 (95% CI, 20.07 to not reached) and 20.27 months (95% CI, 17.51 to 24.18), respectively (HR, 0.54; 95% CI, 0.34 to 0.88; two-sided P = .01). cPFS and OS results were consistent irrespective of PI3K/AKT/PTEN pathway activation status. Grade III-IV adverse events were equivalent between arms (62.2%). The most common adverse events of any grade deemed related to capivasertib were diarrhea, fatigue, nausea, and rash.
Conclusion: The addition of capivasertib to chemotherapy did not extend cPFS in mCRPC irrespective of PI3K/AKT/PTEN pathway activation status. The observed OS result (a secondary end point) will require prospective validation in future studies to address potential for bias.
Trial registration: ClinicalTrials.gov NCT02121639.
Figures
References
- Chi KN Agarwal N Bjartell A, et al. : Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13-24, 2019
- Sartor O, de Bono JS: Metastatic prostate cancer. N Engl J Med 378:1653-1654, 2018
- Davis ID Martin AJ Stockler MR, et al. : Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121-131, 2019
- James ND Spears MR Clarke NW, et al. : Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67:1028-1038, 2015
- Petrylak DP Tangen CM Hussain MH, et al. : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
- Tannock IF de Wit R Berry WR, et al. : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
- de Bono JS Oudard S Ozguroglu M, et al. : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
- Edwards J Krishna NS Witton CJ, et al. : Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9:5271-5281, 2003
- Taylor BS Schultz N Hieronymus H, et al. : Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22, 2010
- Uzoh CC Perks CM Bahl A, et al. : PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU Int 104:556-561, 2009
- Vlietstra RJ van Alewijk DC Hermans KG, et al. : Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723, 1998
- Davies BR Greenwood H Dudley P, et al. : Preclinical pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11:873-887, 2012
- Robertson JFR Coleman RE Cheung KL, et al. : Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER(+) invasive breast cancer (STAKT). Clin Cancer Res 26:1574-1585, 2020
- Banerji U Dean EJ Perez-Fidalgo JA, et al. : A phase I open-label study to identify a dosing regimen of the Pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res 24:2050-2059, 2018
- Hyman DM Smyth LM Donoghue MTA, et al. : AKT inhibition in solid tumors with AKT1 mutations. J Clin Oncol 35:2251-2259, 2017
- Crabb SJ Birtle AJ Martin K, et al. : ProCAID: A phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. Invest New Drugs 35:599-607, 2017
- Scher HI Halabi S Tannock I, et al. : Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
- Eisenhauer EA Therasse P Bogaerts J, et al. : New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
- Royston P, Babiker A: A menu-driven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome. Stata J 2:151-163, 2002
- Abida W Armenia J Gopalan A, et al. : Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017:PO.17.00029, 2017
- Abida W Cyrta J Heller G, et al. : Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A 116:11428-11436, 2019
- Ferraldeschi R Nava Rodrigues D Riisnaes R, et al. : PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 67:795-802, 2015
- Rescigno P Lorente D Dolling D, et al. : Docetaxel Treatment in PTEN- and ERG-aberrant metastatic prostate cancers. Eur Urol Oncol 1:71-77, 2018
- Carver BS Chapinski C Wongvipat J, et al. : Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586, 2011
- de Bono JS De Giorgi U Rodrigues DN, et al. : Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Clin Cancer Res 25:928-936, 2019
- Jones RH Casbard A Carucci M, et al. : Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): A multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 21:345-357, 2020
- Schmid P Abraham J Chan S, et al. : Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. J Clin Oncol 38:423-433, 2020
- Turner NC Alarcon E Armstrong AC, et al. : BEECH: A dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol 30:774-780, 2019
- Kolinsky MP Rescigno P Bianchini D, et al. : A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Ann Oncol 31:619-625, 2020
Source: PubMed